Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» retifanlimab
retifanlimab
FDA unsurprisingly brings down the hammer on Incyte's PD-1 — drawing a line for future accelerated approvals
Endpoints
Mon, 07/26/21 - 09:36 am
Incyte
retifanlimab
FDA
anal cancer
No fast way to eighth place for Incyte
EP Vantage
Fri, 06/25/21 - 10:58 am
Macrogenics
Incyte
retifanlimab
monoclonal antibodies
FDA
FDA slams Incyte's PD-1 over single-arm study, low response and trial deaths
Endpoints
Wed, 06/23/21 - 11:06 am
Incyte
FDA
clinical trials
retifanlimab
Incyte’s PD-(L)1 inhibitor headed for an ODAC showdown next month
Endpoints
Thu, 05/13/21 - 12:06 pm
Incyte
FDA
ODAC
anal cancer
retifanlimab
Incyte makes bid to join the checkpoint inhibitor club
Pharmaforum
Tue, 02/2/21 - 10:25 am
Incyte
FDA
retifanlimab
anal cancer
HIV
HPV
Incyte lands priority review for PD-1 inhibitor in anal cancer
Fierce Biotech
Fri, 01/22/21 - 10:31 am
Incyte
FDA
priority review
anal cancer
retifanlimab